Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Stable liquid technology will enable vaccines to be stored for long periods without refrigeration and reconstitution

A UK vaccine technology that is set to revolutionise the industry has received £950k funding from the Department for International Development (DFID) to bring to production a pentavalent childhood vaccine that can be stored without refrigeration.

25 Oct 2004

Smoking continues to be the largest single cause of death and disease in the EU

Over 650,000 Europeans are killed every year because they smoke, one in seven of all deaths across the EU, and over 13 million more are suffering from a serious, chronic disease as a result of their smoking.

25 Oct 2004

New law will help stop litigation abuse against vaccines

U.S. Senator Larry Craig announced that legislation will be signed into law in a few days by President Bush which will help avert future flu vaccine shortages.

21 Oct 2004

UniSA to officially open its Nano and Bio Materials Centre

Some of the greatest wonders of the 21st century will probably occur on a small scale – in fact a tiny scale – smaller than a human blood cell, right down there at the level of atoms and molecules.

19 Oct 2004

Tiny beads called microspheres could become the new weapon in the fight against liver cancer

The new treatment involves injecting thousands of the beads via an incision into the hepatic artery - the main blood supply for the liver. When the microspheres are injected they are picked up by the blood flow and eventually lodge in the malignant cells of the tumours.

19 Oct 2004

Chiron responds to FDA announcement

Chiron Corporation last Friday provided the following statement in response to an announcement by U.S. health officials on the current influenza vaccine situation.

18 Oct 2004

FDA finds Chiron influenza vaccine unsafe for use

The U.S. Food and Drug Administration has found that none of the influenza vaccine manufactured by the Chiron Corporation for the US market is safe for use.

16 Oct 2004

New Jersey to receive additional flu vaccine

The New Jersey Department of Health and Senior Services (DHSS) received information on October 5, 2004 that, due to manufacturing problems in the United Kingdom, the United States will have only one-half of the expected supply of the influence vaccine available for this year’s flu season.

13 Oct 2004

FDA and MHRA to cooperate efforts to address manufacturing concerns related Chiron's influenza vaccine

The FDA and the U.K's MHRA have announced their intent to continue in a cooperative effort to address the manufacturing quality concerns related to the production of Chiron's influenza vaccine, Fluvirin, at the company's Liverpool facility.

13 Oct 2004

Bandage that uses peptides and collagen, capable of healing wounds and regenerating tissue

Hapto-Biotech, an Israeli start-up company, and New York-based Ortec International Inc., have joined forces to develop a bandage capable of healing wounds and regenerating tissue, using a unique combination of peptides and collagen.

12 Oct 2004

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

United States Department of Health and Human Services has announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), will administer the contracts.

8 Oct 2004

Flu vaccine shortage highlights need to accelerate the approval of affordable generic biopharmaceuticals and vaccines

Following the announcement that the nation is facing a flu vaccine shortage this year, the Generic Pharmaceutical Association (GPhA) renewed its call for the Food and Drug Administration (FDA) and Congress to move forward to accelerate the approval of affordable generic biopharmaceuticals and vaccines.

8 Oct 2004

$10 million to establish a multidisciplinary research program in cancer nanotechnology

The National Institutes of Health (NIH) has awarded scientists from Emory University and the Georgia Institute of Technology two new collaborative research grants, totaling nearly $10 million, to establish a multidisciplinary research program in cancer nanotechnology and to develop a new class of nanoparticles for molecular and cellular imaging.

6 Oct 2004

Ultrasound offers new diagnosis for whiplash injury

Lengthy waits for personal injury compensation after car crashes could be a thing of the past, thanks to research being carried out at The University of Nottingham.

6 Oct 2004

First U.S. program to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada

Illinois Gov. Rod R. Blagojevich and Congressman Rahm Emanuel (D-Chicago) were joined in Chicago today by Wisconsin Governor Jim Doyle to launch the new I-SaveRx prescription drug importation program -- the first program in the nation to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada.

4 Oct 2004

Replacement trend to drive growth in saturated surgical gloves market

Budgetary cuts are the order of the day in the European healthcare industry. Among the many markets affected by this drive to economise, the surgical gloves market is experiencing a sudden drop in prices across Europe.

30 Sep 2004

Cancer vaccine based on listeria bacteria shows promise

An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

29 Sep 2004

ID Biomedical awarded US$9.5 million to develop its cell culture-based influenza vaccine

ID Biomedical announced today that it has been awarded a US$9.5 million grant from the U.S. National Institutes of Health (NIH) to develop its cell culture-based influenza vaccine.

29 Sep 2004

Microfluidics help lab-on-a-chip development skyrocket

Lab-on-a-chip (LOC) development has skyrocketed in the last couple of years due to constant efforts in harnessing microfluidics and µTAS to improve the LOC design and function. The distinct advantages that they bestow on applications are pushing the commercial potential of LOCs.

28 Sep 2004

DuPont CEO says consumers will increasingly depend on biotechnology

DuPont Chairman and Chief Executive Officer Charles O. Holliday, Jr. today said significant progress has been made in demonstrating the benefits of biotechnology, in its acceptance, and in the advancement of new and exciting products the technology is making possible.